Trial Profile
The exploratory study for the drug-predictive markers of TS-1 in metastatic or recurrent breast cancer; Translational biomarker study of SELECT BC trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms SELECT BC-EURECA
- 19 Jul 2016 New trial record
- 07 Jun 2016 Results (n=159) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology